natgillin/translations-raw huggingface dataset:
Quofenix can only be obtained with a prescription and prescribers should take into account official guidance on the use of antibiotics.
Predpisovanje in izdaja zdravila Quofenix je le na recept, poleg tega morajo zdravniki, ki zdravilo predpisujejo, upoštevati uradne smernice za uporabo antibiotikov.
Quofenix is given by infusion (drip) into a vein over one hour every 12 hours.
Zdravilo Quofenix se daje kot enourna (kapalna) infuzija v veno vsakih 12 ur.
What are the risks associated with Quofenix?
Kakšna tveganja so povezana z zdravilom Quofenix?
In the first study involving 660 patients, Quofenix given into a vein was compared with vancomycin plus aztreonam (two other antibiotics) both given into a vein.
V prvi študiji, v katero je bilo vključenih 660 bolnikov, so zdravilo Quofenix v obliki infuzije v veno primerjali z vankomicinom in aztreonamom (drugima dvema antibiotikoma), prav tako dajanima v
For the full list of side effects and restrictions with Quofenix, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Quofenix glejte navodilo za uporabo.
Quofenix is as effective as alternative antibiotics given into a vein in treating acute bacterial skin and skin structure infections and offers the possibility of switching to treatment by mouth, which may be more convenient for the patient and could reduce hospitalisation costs.
Zdravilo Quofenix se je izkazalo za enako učinkovito kot alternativni antibiotiki, dajani v veno, pri zdravljenju akutnih bakterijskih okužb kože in kožnih struktur, ponuja pa tudi možnost peroralnega jemanja, kar je morda bolj priročno za bolnika in lahko zmanjša stroške bolnišničnega zdravljenja.
After treatment for up to 14 days, 58% of patients who received Quofenix were cured of their infection compared with 60% of patients who received vancomycin and aztreonam.
Po zdravljenju do 14 dni je bilo ozdravljenih 58 % bolnikov, ki so prejemali zdravilo Quofenix, v primerjavi s 60 % bolnikov, ki so prejemali vankomicin in aztreonam.
Persistent and disabling side effects have occurred with fluoroquinolone antibiotics in some patients.
Pri nekaterih bolnikih so se pri uporabi fluorokinolonskih antibiotikov pojavili trdovratni in oslabljujoči neželeni učinki.
In the second study involving 850 patients, Quofenix given into a vein for 3 days and afterwards given as tablets by mouth was compared with vancomycin plus aztreonam given into a vein.
V drugi študiji, v katero je bilo vključenih 850 bolnikov, so zdravilo Quofenix v obliki infuzije, dajane v veno tri dni, in nato v obliki tablet, jemanih peroralno, primerjali z vankomicinom in aztreonamom, dajanima v veno.
How does Quofenix work?
Kako zdravilo Quofenix deluje?
How is Quofenix used?
Kako se zdravilo Quofenix uporablja?
patients treated with Quofenix were cured of their infection, compared with 51% of patients treated with vancomycin and aztreonam.
Po 14 dneh zdravljenja je bilo ozdravljenih 52 % bolnikov, ki so prejemali zdravilo Quofenix, v primerjavi z 51 % bolnikov, ki so prejemali vankomicin in aztreonam.
The
Študija
Outcome of a procedure under Article 29 of Directive 2001/83/EC
Izid postopka v skladu s členom 29 Direktive 2001/83/ES
The European Commission issued a decision on 19 November 2012.
Evropska komisija je sklep izdala dne 19. novembra 2012.
However, the Member States were not able to reach an agreement and the Portuguese medicines agency referred the matter to the CHMP for arbitration on 31 May 2012.
Vendar pa države članice niso uspele doseči soglasja, zato je portugalska regulatorna agencija za zdravila 31. maja 2012 zadevo napotila na CHMP v arbitražo.
This is a procedure where one Member State (the ‘reference Member State', in this instance Portugal) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Cyprus, France, Germany, Italy, Sweden and the United Kingdom).
To je postopek, v katerem ena od držav članic („referenčna država članica“, v tem primeru Portugalska) ovrednoti zdravilo z namenom odobritve dovoljenja za promet z zdravilom, ki bo veljavno v tej državi in drugih državah članicah („zadevne države članice“, v tem primeru Ciper, Francija, Nemčija, Italija, Švedska in Združeno kraljestvo).
Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
Zdravili sta biološko enakovredni, kadar dosegata enake ravni zdravilne učinkovine v telesu.
As a result, blood glucose is reduced and this helps to control type 2 diabetes.
Tako se koncentracija glukoze v krvi zniža, kar pomaga pri obvladovanju sladkorne bolezni tipa 2.
Glimepirida Parke-Davis is a ‘generic medicine', which means that it is similar to a ‘reference medicine', already authorised in the EU, called Amaryl.
Zdravilo Glimepirida Parke-Davis je „generično zdravilo“, kar pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v EU, in sicer zdravilu Amaryl.
The active substance, glimepiride, stimulates the pancreas to produce more insulin.
Zdravilna učinkovina, glimepirid, spodbuja trebušno slinavko, da proizvede več insulina.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Glimepirida Parke-Davis outweigh its risks, and that the marketing authorisation can be granted in Portugal and in the following Member States of the EU: Cyprus, France, Germany, Italy, Sweden and the United Kingdom.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi zdravila Glimepirida Parke-Davis odtehtajo njegova tveganja in da se lahko odobri dovoljenje za promet na Portugalskem in v naslednjih državah članicah EU: Ciper, Francija, Nemčija, Italija, Švedska in Združeno kraljestvo.
Glimepirida Parke-Davis is a medicine used to treat type 2 diabetes (a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively).
Glimepirida Parke-Davis je zdravilo, ki se uporablja za zdravljenje sladkorne bolezni tipa 2 (bolezni, pri kateri trebušna slinavka ne proizvaja dovolj insulina za uravnavanje ravni glukoze v krvi ali pri kateri telo insulina ne more učinkovito izrabljati).
Why was Glimepirida Parke-Davis reviewed?
Zakaj je bilo zdravilo Glimepirida Parke-Davis pregledano?
On 19 July 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Glimepirida Parke-Davis (glimepiride, tablets 2, 3 and 4 mg).
Evropska agencija za zdravila je 19. julija 2012 zaključila arbitražni postopek, do katerega je prišlo po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila Glimepirida ParkeDavis (glimepirid, tablete 2, 3 in 4 mg).
What is Glimepirida Parke-Davis?
Kaj je zdravilo Glimepirida Parke-Davis?
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the bioequivalence study conducted with the 1 mg tablet is adequate to show that the higher strengths of Glimepirida Parke-Davis and Amaryl are also bioequivalent.
CHMP je na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave znotraj odbora zaključil, da je študija biološke enakovrednosti, izvedena s tableto 1 mg, ustrezen dokaz, da so večje jakosti zdravil Glimepirida Parke-Davis in Amaryl prav tako biološko enakovredne.
Although the Member States agreed that 1 mg Glimepirida Parke-Davis was bioequivalent to 1 mg Amaryl, concerns remained over whether a bioequivalence study should have been carried out with the highest strength, 4 mg, to show bioequivalence for Glimepirida Parke-Davis 2, 3 and 4 mg with Amaryl at the corresponding doses.
Čeprav so se države članice strinjale, da je zdravilo Glimepirida Parke-Davis 1 mg biološko enakovredno zdravilu Amaryl 1 mg, so ostali pomisleki glede tega, ali bi morala biti študija biološke enakovrednosti izvedena z najvišjo jakostjo 4 mg, da bi dokazali biološko enakovrednost zdravila Glimepirida Parke-Davis 2, 3 in 4 mg zdravilu Amaryl v ustreznih odmerkih.
bioequivalence study submitted by the company was carried out using 1 mg of Glimepirida ParkeDavis, and the results were applied to the higher strengths.
biološke enakovrednosti, ki jo je predložila družba, je bila izvedena ob uporabi 1-miligramske jakosti zdravila Glimepirida Parke-Davis, rezultate pa so nato prenesli na večje jakosti.
The grounds for the referral were concerns over the approach used to demonstrate that Glimepirida Parke-Davis 2, 3 and 4 mg are ‘bioequivalent' to Amaryl at the corresponding doses.
Razlog za napotitev so bili pomisleki glede pristopa, ki je bil uporabljen za dokazovanje, da je zdravilo Glimepirida Parke-Davis 2, 3 in 4 mg „biološko enakovredno“ zdravilu Amaryl v ustreznih odmerkih.
The CHMP therefore concluded that, as Glimepirida Parke-Davis 2, 3 and 4 mg strengths are bioequivalent to the reference medicine, marketing authorisation should be granted in the concerned Member States.
Zato je zaključil, da je zdravilo Glimepirida Parke-Davis v jakostih 2, 3 and 4 mg biološko enakovredno referenčnemu zdravilu, in priporočil, da se glede na to odobri dovoljenje za promet z zdravilom v zadevnih državah članicah.
Parke-Davis submitted an application for Glimepirida Parke-Davis (1, 2, 3 and 4 mg tablets) to the Portuguese medicines regulatory agency for a decentralised procedure.
Družba Parke-Davis je portugalski regulatorni agenciji za zdravila predložila vlogo za decentralizirani postopek za zdravilo Glimepirida Parke-Davis (1, 2, 3 in 4 mg tablete).
List of the names, pharmaceutical forms, strength of the medicinal products, routes of administration, marketing authorisation holders in the Member States
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
* Strength applicable for all countries After reconstitution, 1 dose (0.5 ml) contains: Live attenuated measles virus (Schwarz strain)
* Jakost veljavna v vseh državah Po rekonstituciji 1 odmerek (0,5 ml) vsebuje: Živ oslabljen virus ošpic (sev Schwarz)
not less than 103.7 CCID50
ne manj kot 103,7 CCID50
not less than 103.0 CCID50
ne manj kot 103,0 CCID50
Live attenuated rubella virus (Wistar RA 27/3 strain)
Živ oslabljen virus rdečk (sev Wistar RA 27/3)
Live attenuated mumps virus (RIT 4385 strain, derived from Jeryl Lynn strain)
Živ oslabljen virus mumpsa (sev RIT 4385, pridobljen iz seva Jeryl Lynn)
GlaxoSmithKline BV Huis ter Heideweg 62 3705 LZ Zeist The Netherlands
GlaxoSmithKline BV Huis ter Heideweg 62 3705 LZ Zeist The Netherlands subkutana uporaba
Powder in vials and solvent in prefilled-syringes for solution for injection
Austria prašek v vialah in vehikel v napolnjenih injekcijskih brizgah za raztopino za injiciranje
Powder and solvent for suspension for injection
Bolgarija prašek in vehikel za suspenzijo za injiciranje
This summary was last updated in 05-2011.
Povzetek je bil nazadnje posodobljen 05-2011.
One study was also carried out in women who could not ovulate.
Ena raziskava je bila opravljena tudi pri ženskah, ki niso imele ovulacije.
The European Commission granted a marketing authorisation valid throughout the European Union for Ovitrelle on 2 February 2001.
Evropska komisija je dovoljenje za promet z zdravilom Ovitrelle, veljavno po vsej Evropski uniji, odobrila dne 2. februarja 2001.
The full EPAR for Ovitrelle can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ovitrelle je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Other information about Ovitrelle
Druge informacije o zdravilu Ovitrelle
For more information about treatment with Ovitrelle, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Ovitrelle preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
This is a summary of the European public assessment report (EPAR) for Ovitrelle.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ovitrelle.
The patient or their partner may carry out the injection if they have been trained and have access to expert advice.
Zdravilo lahko injicira tudi bolnica sama ali njen partner, če sta bila za to ustrezno usposobljena in imata na voljo strokovno svetovanje.
The CHMP decided that Ovitrelle's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Ovitrelle večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
What benefit has Ovitrelle shown during the studies?
Kakšne koristi je zdravilo Ovitrelle izkazalo med študijami?
Ovitrelle has mainly been studied in women undergoing fertility treatment (1,140 patients).
Zdravilo Ovitrelle je bilo proučevano predvsem pri ženskah, ki so se zdravile zaradi težav s plodnostjo (pri 1 140 bolnicah).
It must not be used when a response cannot be obtained (such as in ovarian failure).
Ne sme se uporabljati, kadar terapevtskega odziva ni mogoče doseči (npr. pri insuficienci jajčnikov).
Treatment with Ovitrelle should be carried out under the supervision of a doctor who has experience in the treatment of fertility problems.
Zdravljenje z zdravilom Ovitrelle mora izvajati zdravnik z izkušnjami pri zdravljenju težav s plodnostjo.
The most common side effects with Ovitrelle (seen in between 1 and 10 patients in 100) are reactions at the injection site, headache, tiredness, vomiting, nausea (feeling sick), abdominal pain (stomach ache) and ovarian hyperstimulation syndrome (such as feeling sick, weight gain and diarrhoea).
Najpogostejši neželeni stranski učinki (opaženi pri 1 do 10 bolnicah od 100) so reakcije ali bolečina na mestu injiciranja, glavobol, utrujenost, bruhanje, slabost, bolečina v trebuhu in sindrom hiperstimulacije jajčnikov (tj. slabost, pridobivanje telesne teže, driska).
Ovarian hyperstimulation syndrome occurs when the ovaries over respond to treatment, especially when medicines to trigger ovulation have been used.
Sindrom ovarijske hiperstimulacije nastopi, kadar se jajčniki preveč odzovejo na zdravljenje, še posebej če so uporabljena zdravila za sprožitev ovulacije.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ovitrelle.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Ovitrelle, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Ovitrelle was as effective as urinary hCG in triggering ovulation, and the 250-microgram dose of Ovitrelle was as effective as the 500-microgram dose.
Zdravilo Ovitrelle je bilo pri sprožanju ovulacije enako učinkovito kot iz urina pridobljeni hCG, 250mikrogramski odmerek zdravila Ovitrelle pa je bil enako učinkovit kot 500-mikrogramski odmerek.
EPAR summary for the public choriogonadotropin alfa
Povzetek EPAR za javnost horiogonadotropin alfa
Ovitrelle is given by injection under the skin.
Zdravilo Ovitrelle se daje s subkutano injekcijo (pod kožo).
Because of its similarity to luteinising hormone (LH), Ovitrelle is also used to trigger ovulation.
Zaradi podobnosti z luteinizirajočim hormonom (LH) se zdravilo Ovitrelle uporablja tudi za sprožitev ovulacije.
The effectiveness of Ovitrelle was measured by looking at how many eggs were released.
Učinkovitost zdravila Ovitrelle so merili s številom sproščenih jajčec.
Ovitrelle should not be used in people who may be hypersensitive (allergic) to choriogonadotropin alfa or any of the other ingredients.
Zdravila Ovitrelle ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) na horiogonadotropin alfa ali katero koli drugo sestavino zdravila.
What is the risk associated with Ovitrelle?
Kakšna tveganja so povezana z zdravilom Ovitrelle?
The choriogonadotropin alfa in Ovitrelle is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes cell able to produce it.
Zdravilno učinkovino horiogonadotropin alfa v zdravilu Ovitrelle proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“: izdela ga celica, ki je prejela gen (DNK), s katerim lahko tvori horiogonadotropin alfa.
Ovitrelle (250 micrograms or 500 micrograms) was compared with the natural hCG hormone that had been extracted from urine.
Zdravilo Ovitrelle (250- in 500-mikrogramski odmerek) so primerjali z naravnim hormonom hCG, ki so ga pridobili iz urina.
Ovitrelle is a medicine that contains the active substance choriogonadotropin alfa.
Ovitrelle je zdravilo, ki vsebuje zdravilno učinkovino horiogonadotropin alfa.
The active substance in Ovitrelle, choriogonadotropin alfa, is a copy of the natural hormone human chorionic gonadotropin (hCG), also known as the ‘pregnancy' hormone, which helps to maintain pregnancy.
Zdravilna učinkovina horiogonadotropin alfa v zdravilu Ovitrelle je posnetek naravnega humanega horionskega gonadotropina (hCG), znanega tudi pod imenom „nosečnostni” hormon, ki pomaga vzdrževati nosečnost.
It can be used in women who are undergoing fertility treatment (such as in vitro fertilisation), and in women who are anovulatory (do not produce eggs) or oligo ovulatory (rarely produce eggs).
Lahko se uporablja pri ženskah, ki se zdravijo zaradi neplodnosti (postopki asistirane reprodukcije, kot je npr. oploditev in vitro), in pri ženskah brez ovulacije (ne tvorijo jajčec) ali z oligoovulacijo (redko tvorijo jajčeca).
Ovitrelle must also not be used in patients with active thromboembolic disorders (problems with blood clotting).
Zdravila Ovitrelle se prav tako ne sme uporabljati pri bolnicah z aktivnimi tromboemboličnimi motnjami (strdki).
A dose of 250 micrograms is given 24 to 48 hours after the ovaries have produced follicles that are mature enough (eggs ready for ovulation).
Ena viala zdravila Ovitrelle (250 mikrogramov) se injicira 24 do 48 ur potem, ko so jajčniki proizvedli dovolj zrele folikle (jajčeca, pripravljena za ovulacijo).
It must not be used in patients with tumours of the hypothalamus, pituitary gland, ovary, womb or breast.
Zdravila Ovitrelle ne smejo uporabljati bolniki, ki imajo tumorje hipotalamusa, hipofize, jajčnikov, maternice ali dojk.
Ovitrelle is used in women who have received treatment to stimulate their ovaries, to trigger ovulation (the release of eggs by the ovaries) and the development of a special structure on the ovary (the corpus luteum) that helps pregnancy.
Zdravilo Ovitrelle se uporablja pri ženskah, ki so že prejemale zdravljenje za stimulacijo jajčnikov, za sprožitev ovulacije (sprostitve jajčec iz jajčnikov) in za razvoj posebne strukture na jajčniku (rumeno telesce), kar pomaga pri zanositvi.
In women undergoing fertility treatment, this is generally 24 to 48 hours after stopping treatment to stimulate the ovaries (such as a follicle stimulating hormone [FSH] or human menopausal gonadotrophin [hMG] preparation).
Pri ženskah, ki se zdravijo zaradi težav s plodnostjo, se to običajno zgodi 24 do 48 ur po končanem predhodnem zdravljenju za stimulacijo jajčnikov (npr. s pripravkom, ki vsebuje folikle stimulirajoči hormon (FSH) ali humani menopavzni gonadotropin (hMG)).
In anovulatory women, ovulation was seen in 92% of the women treated with Ovitrelle.
Pri 92 % žensk brez ovulacije, ki so se zdravile z zdravilom Ovitrelle, je prišlo do ovulacije.
It must not be used in women with ovarian enlargement or cysts not due to polycystic ovarian disease, unexplained vaginal bleeding, or who have had an ectopic pregnancy (a pregnancy that develops outside the womb) in the previous three months.
Ravno tako se ne sme uporabljati v primeru povečanja jajčnikov ali ciste, ki ni posledica policistične bolezni jajčnikov, kakor tudi ne v primeru nepojasnjene krvavitve iz nožnice ali pri ženskah, ki so imele v zadnjih 3 mesecih zunajmaternično nosečnost.
It is available as a powder and solvent to be made up into a solution for injection and as a solution in a pre-filled syringe or pre-filled pen.
Na voljo je v obliki praška in vehikla, ki se zmešata v raztopino za injiciranje, ter napolnjene brizge ali peresnika.
Why has Ovitrelle been approved?
Zakaj je bilo zdravilo Ovitrelle odobreno?
How does Ovitrelle work?
Kako zdravilo Ovitrelle deluje?
What is Ovitrelle used for?
Za kaj se zdravilo Ovitrelle uporablja?
How has Ovitrelle been studied?
Kako je bilo zdravilo Ovitrelle raziskano?
How is Ovitrelle used?
Kako se zdravilo Ovitrelle uporablja?
What is Ovitrelle?
Kaj je zdravilo Ovitrelle?
This overview was last updated in September 2019.
Povzetek je bil nazadnje posodobljen septembra 2019.
Studies have shown the start of protection to be from between 24 days of age and 28 days of age.
Študije so pokazale začetek zaščite med 24 in 28 dnem starosti.
Virulent means that the virus is capable of producing severe disease.
Virulenten pomeni, da je virus sposoben povzročiti hudo bolezen.
Further information on Gumbohatch can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/gumbohatch.
Nadaljnje informacije o cepivu Gumbohatch so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/gumbohatch.
Protection against IBD starts from between 24 to 28 days of age and lasts up to 43 days of age.
Zaščita pred virusom IBD se začne pri starosti od 24 do 28 dni in traja do starosti 43 dni.
Gumbohatch was investigated in 5 laboratory and 3 field studies.
Cepivo Gumbohatch je bilo preiskano v petih laboratorijskih in treh terenskih študijah.
This loss of lymphocytes does not cause immunosuppression in the chickens.
Ta izguba limfocitov ne povzroča imunosupresije pri piščancih.
The European Medicines Agency decided that Gumbohatch's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi cepiva Gumbohatch večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The start of protection depends on the initial maternal antibody level of the batch of chickens and even then will be different for individual chickens.
Začetek zaščite je odvisen od začetne ravni maternalnih protiteles v seriji piščancev in tudi takrat bo zaščita pri vsakem piščancu nastopila drugače.
After handling vaccinated birds or their litter, hands should be washed and disinfected because the virus is excreted by vaccinated birds for up to 3 weeks.
Po rokovanju s cepljenimi pticami ali njihovim leglom, si je treba roke oprati in razkužiti, ker cepljene ptice virus izločajo do tri tedne.
What is the withdrawal period in food-producing animals?
Kakšna je karenca pri živalih, namenjenih za proizvodnjo hrane?
Vaccines work by preparing the immune system (the body's natural defences) to defend itself against a specific disease.
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) pripravijo na to, da se brani pred določeno boleznijo.
Gumbohatch received a marketing authorisation valid throughout the EU on 12 November 2019.
Cepivo Gumbohatch je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 12/11/2019.
The vaccine reduces signs of the disease and damage to the bursa of Fabricius, an organ only present in birds which is part of their immune system.
Cepivo zmanjša znake bolezni in poškodbo burze Fabricij, organa, ki je prisoten le pri pticah in je del njihovega imunskega sistema.
Other information about Gumbohatch
Druge informacije o zdravilu Gumbohatch
For more information about using Gumbohatch, see the package leaflet or contact your veterinarian or pharmacist.
Za več informacij glede uporabe cepiva Gumbohatch glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.